{"public_id":"cl_465a97d2d0fc03170dfc7a2f2b972a0a","status":"active","superseded_by_public_id":null,"corpus_id":75311601,"text":"A single intravenous infusion of cA2 produced substantially higher four-week clinical response rates than placebo in moderate-to-severe treatment-resistant Crohn's disease.","confidence":0.99,"paper":{"corpus_id":75311601,"title":"A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease","url":"https://sah.borca.ai/papers/75311601"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.99,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_519269fc761d2421222a10b7de7c3605","name":"chimeric monoclonal antibody cA2","description":"A chimeric monoclonal antibody directed against tumor necrosis factor alpha and tested as a treatment for Crohn's disease.","types":["drug","therapeutic antibody"],"url":"https://sah.borca.ai/concepts/co_519269fc761d2421222a10b7de7c3605"},{"public_id":"co_7b8c4d5d73381dbe60954c5d07f78342","name":"Crohn's disease","description":"An inflammatory bowel disease studied here in moderate-to-severe, treatment-resistant patients.","types":["disease"],"url":"https://sah.borca.ai/concepts/co_7b8c4d5d73381dbe60954c5d07f78342"},{"public_id":"co_7c99d0e1d114f57ba250e61938f6b49b","name":"clinical response","description":"The primary endpoint defined by a reduction of at least 70 points in the Crohn's Disease Activity Index without concomitant medication changes.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_7c99d0e1d114f57ba250e61938f6b49b"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_465a97d2d0fc03170dfc7a2f2b972a0a"}